Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 3, 2011, Pages 284-294

  Bosnjakovic, Admira ^a   Mishra, Manoj K ^a   Ren, Weiping ^a   Kurtoglu, Yunus E ^a   Shi, Tong ^a   Fan, Dianna ^a   Kannan, Rangaramanujam M ^a  

^a Wayne State University   (United States)

Author keywords

Drug delivery; Erythromycin; Macrophages; PAMAM dendrimer; Periprosthetic inflammation

Indexed keywords

AMINE GROUPS; ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY EFFECTS; ANTIBACTERIAL PROPERTIES; BACTERIAL GROWTH; BIFUNCTIONAL; ERYTHROMYCIN; ESTER BONDS; GLUTARATE; INFECTIOUS DISEASE; INTRACELLULAR DELIVERY; NANO DEVICE; PAMAM DENDRIMER; PERIPROSTHETIC INFLAMMATION; PHARMACOLOGICAL ACTIVITY; POLY(AMIDO AMINE); POLYAMIDOAMINE DENDRIMERS; PRODRUGS; ZONE OF INHIBITIONS;

DRUG DELIVERY; MACROPHAGES; ORGANIC COMPOUNDS; PATHOLOGY;

DENDRIMERS;

DENDRIMER; ERYTHROMYCIN; LIPOPOLYSACCHARIDE; NITRITE; POLYAMIDOAMINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; LIGHT SCATTERING; MACROPHAGE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PERIPROSTHETIC INFLAMMATION; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL DEATH; DENDRIMERS; DRUG DELIVERY SYSTEMS; ERYTHROMYCIN; INFLAMMATION; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; NITRITES; NYLONS; PARTICLE SIZE; POLYAMINES; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCUS AUREUS; STATIC ELECTRICITY;

BACTERIA (MICROORGANISMS);

EID: 79956357853     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2010.10.008     Document Type: Article

References (49)

1. Wooley P.H., Schwarz E.M. Aseptic loosening. Gene Ther 2004, 11:402-407.
2. Schwarz E.M. What potential biologic treatments are available for osteolysis?. J Am Acad Orthop Surg 2008, 16(Suppl. 1):S72-S75.
3. Pollice P.F., Rosier R.N., Looney R.J., Puzas J.E., Schwarz E.M., O'Keefe R.J. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am 2001, 83:1057-1061.
4. Childs L.M., Goater J.J., O'Keefe R.J., Schwarz E.M. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 2001, 16:338-347.
5. Yatsunami J., Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res 2001, 21:4253-4258.
6. Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol 2001, 121:83-92.
7. Giamarellos-Bourboulis E.J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
8. Dette G.A., Knothe H., Kellner H.M. Whole body tissue distribution of [14C]-erythromycin in the guinea pig. An autoradiographic study. Arzneimittelforschung 1987, 37:524-527.
9. Cuffini A.M., Tullio V., Cimino F., Carlone N.A. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 1. Uptake of 3H-macrolides by human macrophages. Microbios 1989, 57:167-178.
10. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998, 4:116-121.
11. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1989, 157:1829-1832.
12. Ren W.P., Li X.Y., Chen B.D., Wooley P.H. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NFkB activity. J Orthop Res 2004, 22:21-29.
13. Aoki Y., Kao P.N. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999, 43:2678-2684.
14. Nakashima Y., Sun D.H., Trindade M.C., Maloney W.J., Goodman S.B., Schurman D.J., et al. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am 1999, 81:603-615.
15. Shinkai M., Henke M.O., Rubin B.K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008, 117:393-405.
16. Ren W.P., Bin W., Mayton L., Wooley P.H. Erythromycin (EM) inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res 2006, 24:280-290.
17. Ren W.P., Blasier R., Peng X., Shi T., Wooley P.H., Markel D.C. Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses. Bone 2009, 44:671-677.
18. Markel D.C., Zhang R., Shi T., Hawkins M., Ren W.P. Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis. Inflamm Res 2009, 58:413-421.
19. Ren W.P., Markel D.C., Zhang R., Peng X., Wu B., Monica H., et al. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials 2006, 27:5161-5169.
20. Svenson S., Tomalia D.A. Dendrimers in biomedical applications and reflections on the field. Adv Drug Deliv Rev 2005, 57:2106-2129.
21. Esfand R., Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001, 6:427-436.
22. Gurdag S., Khandare J., Stapels S., Matherly L.H., Kannan R.M. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 2006, 17:275-283.
23. Khandare J., Kolhe P., Pillai O., Kannan S., Lieh-Lai M., Kannan R.M. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 2005, 16:330-337.
24. Kolhe P., Khandare J., Pillai O., Kannan S., Lieh-Lal M., Kannan R.M. Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials 2006, 27:660-669.
25. Kobayashi H., Kawamoto S., Choyke P.L., Sato N., Knopp M.V., Star R.A., et al. Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 2003, 50:758-766.
26. Talanov V.S., Regino C.A.S., Kobayashi H., Bernardo M., Choyke P.L., Brechbiel M.W. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett 2006, 6:1459-1463.
27. Wang B., Navath R.S., Menjoge A.R., Balakrishnan B., Bellair R., Dai H., et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010, 395:298-308.
28. Yoon H.C., Hong M.Y., Kim H.S. Affinity biosensor for avidin using a double functionalized dendrimer monolayer on a gold electrode. Anal Biochem 2000, 282:121-128.
29. Zhu Y., Zhu H., Yang X., Xu L., Li C. Sensitive biosensors based on (dendrimer encapsulated Pt nanoparticles)/enzyme multilayers. Electroanalysis 2007, 19:698-703.
30. Han H.J., Kannan R.M., Wang S., Mao G., Kusanovic J.P., Romero R. Multifunctional dendrimer-templated antibody presentation on biosensor surfaces for improved biomarker detection. Adv Funct Mater 2010, 20:409-421.
31. Jain N.K., Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol 2008, 4:1035-1052.
32. Gillies E.R., Fréchet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10:35-43.
33. Chauhan A.S., Sridevi S., Chalasani K.B., Jain A.K., Jain S.K., Jain N.K., et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003, 90:335-343.
34. Alving R.C., Steckt A.E., Chapman L.W., Waits B.V., Hendrickst D.L., Swartz M.G., et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA 1978, 75:2959-2963.
35. Patri K.A., Kukowska-Latallo F.J., Baker J.R. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and noncovalent drug inclusion complex. Adv Drug Deliv Rev 2005, 57:2203-2214.
36. Kurtoglu Y.E., Mishra M.K., Kannan S., Kannan R.M. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm 2010, 384:189-194.
37. Navath R.S., Kurtoglu Y.E., Wang B., Kannan S., Romero R., Kannan R.M. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem 2008, 19:2446-2455.
38. Patri A.K., Kukowska-Latallo J.F., Baker J.R. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005, 57:2203-2214.
39. Dai H, Navath RS, Balakrishnan B, Guru BR, Mishra MK, Romero R, et al. Intrinsic targeting of neuroinflammation by polyamidoamine dendrimers in a rabbit model of cerebral palsy. Fut Med Nanomed (June 2010). http://www.kannangroup.com/publications.html.
40. Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J.W., et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000, 65:133-148.
41. El-Sayed M., Ginski M., Rhodes C.A., Ghandehari H. Influence of surface chemistry of poly(amidoamine) dendrimers on Caco-2 cell monolayers. J Bioact Compat Polym 2003, 18:7-22.
42. Ogura H., Nagai S., Takeda K.A. Novel reagent (N-succinimidyl diphenyl phosphate) for synthesis of active ester and peptide. Tetrahedron Lett 1980, 21:1467-1468.
43. Alvarez-Elcoro S., Enzler M.J. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clin Proc 1999, 74:613-634.
44. Jones P.H., Baker E.J., Rowley E.K., Perun T.J. Chemical modifications of erythromycin antibiotics. 3. Synthesis of 4'' and 11 esters of erythromycin A and B. J Med Chem 1972, 15:631-634.
45. Lewis C.A., Miller S.J. Site-selective derivatization and remodeling of erythromycin A by using simple peptide-based chiral catalysts. Angew Chem Int Ed 2006, 45:5616-5619.
46. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15:171-185.
47. Najlah M., Freeman S., Attwood D., D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 2007, 336:183-190.
48. Najlah M., Freeman S., Attwood D., D'Emanuele A. Synthesis, characterization and stability of dendrimer prodrugs. Int J Pharm 2006, 308:175-182.
49. Tomalia D.A., Naylor A.M., Goddard W.A. Starburst dendrimers: molecular level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed 1990, 29:138-175.